231.88
1.21%
+2.855
전일 마감가:
$229.03
열려 있는:
$230.88
하루 거래량:
136.31K
시가총액:
$12.01B
수익:
$4.13B
순이익/손실:
$474.62M
주가수익비율:
24.59
EPS:
9.43
순현금흐름:
$365.37M
1주 성능:
-0.32%
1개월 성능:
-14.45%
6개월 성능:
+34.31%
1년 성능:
+21.93%
Charles River Laboratories International Inc. Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc.
전화
781-222-6000
주소
251 Ballardvale Street, Wilmington, MA
Charles River Laboratories International Inc. Stock (CRL) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
2023-09-13 | 개시 | TD Cowen | Market Perform |
2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
2022-08-25 | 개시 | Credit Suisse | Outperform |
2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2022-05-24 | 개시 | Guggenheim | Neutral |
2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
2022-04-07 | 개시 | Stephens | Overweight |
2022-02-17 | 재확인 | BofA Securities | Buy |
2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
2022-02-17 | 재확인 | Deutsche Bank | Buy |
2022-02-17 | 재확인 | Morgan Stanley | Overweight |
2022-02-17 | 재확인 | UBS | Buy |
2021-08-05 | 재개 | Credit Suisse | Neutral |
2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2020-03-02 | 개시 | Deutsche Bank | Buy |
2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
2020-01-08 | 개시 | Wells Fargo | Overweight |
2020-01-07 | 개시 | Citigroup | Buy |
2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2019-06-10 | 개시 | SVB Leerink | Outperform |
2019-04-30 | 재개 | Evercore ISI | Outperform |
2018-12-14 | 개시 | Deutsche Bank | Buy |
2018-10-09 | 개시 | UBS | Neutral |
2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc. 주식(CRL)의 최신 뉴스
ICLR vs. CRL: Which Stock Is the Better Value Option?
Zacks Investment Research
Teladoc (TDOC) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
Zacks Investment Research
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Zacks Investment Research
Here's Why You Should Retain Charles River (CRL) Stock Now
Zacks Investment Research
ICLR or CRL: Which Is the Better Value Stock Right Now?
Zacks Investment Research
Charles River Laboratories International Inc. (CRL) 재무 분석
Charles River Laboratories International Inc. (CRL) 매출 2024
CRL은 2023-12-31 종료 분기에 대해 매출(지난 12개월)이 4.13B 달러로 보고했으며, 전년대비 +3.86% 상승했습니다.
Charles River Laboratories International Inc. (CRL) 순이익 2024
CRL은 2023-12-31 종료 분기에 대해 순이익(지난 12개월)이 474.62M 달러로 보고했으며, 전년대비 -2.39% 감소했습니다.
Charles River Laboratories International Inc. (CRL) 현금흐름 2024
2023-12-31 종료 분기에 CRL은 현금흐름(지난 12개월)으로 365.37M 달러를 기록했으며, 전년 대비 +23.89% 증가했습니다.
Charles River Laboratories International Inc. (CRL) 주당 순이익 2024
CRL이 보고한 2023-12-31 종료 분기의 주당 순이익(지난 12개월)은 9.23달러이며, 전년 대비 -2.53% 감소했습니다.
Charles River Laboratories International Inc. 주식 (CRL) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Knell Michael Gunnar | CSVP&Chief Accounting Officer |
Mar 08 '24 |
Sale |
267.52 |
808 |
216,156 |
7,024 |
Knell Michael Gunnar | CSVP&Chief Accounting Officer |
Mar 04 '24 |
Sale |
261.05 |
2,750 |
717,890 |
7,832 |
Creamer Victoria L | EVP & Chief People Officer |
Feb 29 '24 |
Sale |
253.70 |
5,000 |
1,268,500 |
13,550 |
Parisotto Shannon M | CEVP, Disc & Safety Assessment |
Feb 29 '24 |
Sale |
253.45 |
3,786 |
959,545 |
4,792 |
Barbo William D | Corporate Executive VP & CCO |
Feb 22 '24 |
Sale |
248.50 |
4,050 |
1,006,425 |
22,879 |
Parisotto Shannon M | CEVP, Disc & Safety Assessment |
Feb 15 '24 |
Option Exercise |
144.67 |
5,882 |
850,949 |
8,478 |
Parisotto Shannon M | CEVP, Disc & Safety Assessment |
Feb 15 '24 |
Sale |
241.20 |
5,882 |
1,418,767 |
2,596 |
LaPlume Joseph W | EVP, Corp Strategy & Develop |
Feb 15 '24 |
Sale |
238.93 |
838 |
200,223 |
24,620 |
FOSTER JAMES C | Chairman, President and CEO |
Jan 29 '24 |
Option Exercise |
144.67 |
17,436 |
2,522,466 |
227,827 |
Girshick Birgit | Corporate Executive VP & COO |
Jan 10 '24 |
Option Exercise |
215.19 |
5,916 |
1,273,064 |
50,365 |
자본화:
|
볼륨(24시간):